Spoken Alpha
Grace Therapeutics, Inc.
Grace Therapeutics develops and commercializes drug candidates for rare and orphan diseases using proprietary formulation and drug delivery technologies applied to existing approved pharmaceutical compounds.
Grace Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $40.8M market cap.
GRCE missed consensus EPS by 1.0% in Q1 FY2027, reported Aug 12, 2026.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-10-04.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add GRCE, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for GRCE.
$ curl https://api.spokenalpha.com/v1/companies/GRCEFAQ
Spoken Alpha indexes GRCE's earnings call transcripts at https://spokenalpha.com/companies/GRCE. Each call links to attributed speakers and parsed analyst Q&A. Grace Therapeutics, Inc.'s own investor relations page is at https://www.gracetx.com/investors.
Grace Therapeutics, Inc. (GRCE) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2027 | 2026-08-12 | $-0.91 | $-0.18 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2026 | 2026-06-17 | $-0.08 | $-0.20 | +60.0% | $0 | — | — | EODHD |
| Q3 FY2026 | 2026-02-11 | $-0.19 | $-0.39 | +51.3% | $0 | — | — | EODHD |
| Q2 FY2026 | 2025-11-12 | $-0.08 | $-0.34 | +76.5% | $0 | — | — | EODHD |
| Q1 FY2026 | 2025-08-11 | $-0.29 | $-0.31 | +6.5% | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-06-22 | $0.05 | $-0.40 | +100.0% | $8.0K | — | — | EODHD |
| Q3 FY2025 | 2025-02-16 | $-0.51 | $-0.46 | -11.7% | $0 | — | — | EODHD |
| Q2 FY2025 | 2024-11-12 | $-0.42 | $-0.50 | +16.8% | $0 | — | — | EODHD |
| Q1 FY2025 | 2024-08-08 | $-0.33 | $-0.36 | +8.3% | $0 | — | — | EODHD |
| Q4 FY2024 | 2024-06-20 | $-0.36 | $-0.47 | +24.1% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-02-11 | $-0.28 | $-0.31 | +9.7% | $0 | — | — | EODHD |
| Q2 FY2024 | 2023-11-12 | $-0.31 | $-0.35 | +11.4% | $0 | — | — | EODHD |
| Q1 FY2024 | 2023-08-10 | $-0.48 | $-0.37 | -29.7% | $0 | — | — | EODHD |
| Q4 FY2023 | 2023-06-22 | $-0.65 | $-0.14 | -100.0% | — | — | — | EODHD |
| Q3 FY2023 | 2023-02-13 | $-0.72 | $-1.01 | +28.7% | — | — | — | EODHD |
| Q2 FY2023 | 2022-11-13 | $-0.11 | — | — | — | — | — | EODHD |
| Q1 FY2023 | 2022-08-10 | $-0.10 | — | — | — | — | — | EODHD |
| Q4 FY2022 | 2022-06-20 | $-0.31 | $-1.00 | +69.0% | — | — | — | EODHD |
| Q3 FY2022 | 2022-02-13 | $-0.69 | $-0.62 | -11.3% | — | — | — | EODHD |
| Q2 FY2022 | 2021-11-09 | $-0.03 | — | — | — | — | — | EODHD |
Source: EODHD. GRCE reported actuals as published; sparse fields render as —.